Form 4: Codexis Executive Alison Moore Reports Stock and Option Awards

Alison Moore, Chief Technical Officer of Codexis, reports acquisition of stock and option awards in a recent SEC Form 4 filing.

Summary

• Alison Moore, the Chief Technical Officer of Codexis, Inc., filed a Form 4 with the SEC.
• The filing reports the acquisition of 26,875 shares of common stock and options to purchase 161,250 shares of common stock on February 5, 2025.
• The common stock was acquired at a price of $0.
• The stock options have an exercise price of $4.37 and expire on February 5, 2035.
• The restricted stock units vest in three equal annual installments from the grant date, contingent upon continued employment.
• The stock options vest 25% on the first anniversary of the grant date, and then 1/48th monthly thereafter, contingent upon continued employment.
• Following the reported transactions, Moore beneficially owns 175,571 shares of common stock and options to purchase 161,250 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard SEC filing detailing stock and option grants, which is neither overtly positive nor negative.

Positives

• The acquisition of stock and options by a key executive could be seen as a positive sign, indicating confidence in the company's future prospects.

Risks

• The vesting of the stock and options is contingent upon continued employment, which introduces a risk factor related to executive retention.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the vesting schedules of the stock and options suggest a multi-year commitment from the executive.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in publicly traded companies. It provides transparency into the equity holdings of company insiders.

Comparison to Industry Standards

• Stock option grants and restricted stock units are standard components of executive compensation packages in the biotechnology industry, used to align management's interests with those of shareholders.
• Companies like Amyris and Ginkgo Bioworks also utilize similar equity-based compensation strategies for their executives.
• The vesting schedules described are typical, with annual or monthly vesting over a period of several years.

Stakeholder Impact

• Shareholders may view the equity grants as a way to incentivize management and align their interests with the company's long-term success.
• Employees may see the grants as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Form 4, SEC, Codexis, Alison Moore, stock options, restricted stock units, beneficial ownership, CDXS